BIOLOGIC/DISEASE-MODIFYING ANTIRHEUMATIC DRUG
Amjevita is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to reduce signs and symptoms, induce major clinical response, reduce joint damage, and improve physical functioning in adults with moderately to severely active rheumatoid arthritis. Amjevita is also referred to by its drug name, adalimumab-atto.
Amjevita is a biosimilar of Humira. As defined by the FDA, a biosimilar is a biological product that is approved based on a showing that it is highly similar to an already-approved biological product.
Amjevita is considered a biologic disease-modifying antirheumatic drug (DMARD). Amjevita is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Amjevita is believed to work by inhibiting tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.
How do I take it?
Prescribing information states that Amjevita is administered as a subcutaneous injection (under your skin) once every two weeks.
Amjevita comes in a prefilled, single-use syringe. Your doctor will show you how to administer it.
The FDA-approved label for Amjevita lists common side effects including respiratory tract infections, sinusitis, injection site reactions, headache, and rash.
Rare but serious side effects listed for Amjevita include severe infections, heart failure, increased risk for lymphoma and other cancers, lupus-like syndrome, severe allergic reactions, and the development of nerve conditions such as multiple sclerosis.
For more details about this treatment, visit:
Amjevita (Adalimumab-atto) — GoodRx